Radiopharm Theranostics (ASX:RAD) said that a recently published study reported a methodology for detecting brain metastases using its proprietary radiotracer 18F-RAD101, according to a Monday Australian bourse filing.
A study published in the European Journal of Nuclear Medicine and Molecular Imaging investigated the imaging characteristics of brain metastases in 12 patients with no prior brain radiotherapy and 10 patients who had previously been treated with brain radiation.
The use of the radiotracer with Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging detected all brain metastases, regardless of the tumor of origin, with a high tumor-to-background ratio, the filing said.
The biopharmaceuticals firm's phase 2b clinical trial to evaluate the diagnostic performance of the radiotracer in patients with suspected recurrent brain metastasis from solid tumors of different origins is currently recruiting in the US.
The firm's shares fell 4% in recent trading on Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。